A Novel Nomogram to Predict Prognosis of Advanced Hepatocellular Carcinoma Treated with Intensity-Modulated Radiotherapy Plus Anti-PD1

References

• Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–172. doi:10.1038/s41571-021-00573-2
   PubMed Web of Science ®Google Scholar
• Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surgery Nutrition. 2020;9(4):452–463. doi:10.21037/hbsn-20-480
   PubMed Web of Science ®Google Scholar
• Zhong JH, Peng NF, You XM, et al. Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: a real-world study. Oncotarget. 2017;8(11):18296–18302. doi:10.18632/oncotarget.15433
   PubMedGoogle Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. New Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/s0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. New Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Chen W, Chiang CL, Dawson LA. Efficacy and safety of radiotherapy for primary liver cancer. Chine Clin Oncol. 2021;10(1):9. doi:10.21037/cco-20-89
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label Phase 2 trial. Lancet Oncol. 2018;19(7):940–952. doi:10.1016/s1470-2045(18)30351-6
   PubMed Web of Science ®Google Scholar
• Yau T, Hsu C, Kim TY, et al. Nivolumab in advanced hepatocellular carcinoma: sorafenib-experienced Asian cohort analysis. J Hepatol. 2019;71(3):543–552. doi:10.1016/j.jhep.2019.05.014
   PubMed Web of Science ®Google Scholar
• Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020;21(4):571–580. doi:10.1016/s1470-2045(20)30011-5
   PubMed Web of Science ®Google Scholar
• Lee YH, Tai D, Yip C, Choo SP, Chew V. Combinational Immunotherapy for Hepatocellular Carcinoma: radiotherapy, Immune Checkpoint Blockade and Beyond. Front Immunol. 2020;11:568759. doi:10.3389/fimmu.2020.568759
   PubMed Web of Science ®Google Scholar
• McLaughlin M, Patin EC, Pedersen M, et al. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer. 2020;20(4):203–217. doi:10.1038/s41568-020-0246-1
   PubMed Web of Science ®Google Scholar
• Li JX, Deng WX, Huang ST, et al. Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study. Radiat Oncol. 2022;17(1):106. doi:10.1186/s13014-022-02075-6
   PubMed Web of Science ®Google Scholar
• Li JX, Su TS, Gong WF, et al. Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial. Hepatol Internat. 2022;16(5):1179–1187. doi:10.1007/s12072-022-10396-7
   PubMed Web of Science ®Google Scholar
• Li JX, He ML, Qiu MQ, et al. Prognostic value of a nomogram based on peripheral blood immune parameters in unresectable hepatocellular carcinoma after intensity-modulated radiotherapy. BMC Gastroenterol. 2022;22(1):510. doi:10.1186/s12876-022-02596-0
   PubMed Web of Science ®Google Scholar
• Muhammed A, D’Alessio A, Enica A, et al. Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma. Expert Rev Mol Diagn. 2022;22(3):253–264. doi:10.1080/14737159.2022.2049244
   PubMed Web of Science ®Google Scholar
• Mattos ÂZ, Debes JD, Boonstra A, Vogel A, Mattos AA. Immune aspects of hepatocellular carcinoma: from immune markers for early detection to immunotherapy. World J Gastrointest Oncol. 2021;13(9):1132–1143. doi:10.4251/wjgo.v13.i9.1132
   PubMed Web of Science ®Google Scholar
• Su TS, Li LQ, Liang SX, et al. A Prospective Study of Liver Regeneration After Radiotherapy Based on a New (Su’S) Target Area Delineation. Front Oncol. 2021;11:680303. doi:10.3389/fonc.2021.680303
   PubMed Web of Science ®Google Scholar
• Cheng AL, Guan Z, Chen Z, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the Phase III Sorafenib Asia-Pacific trial. Eur J Cancer. 2012;48(10):1452–1465. doi:10.1016/j.ejca.2011.12.006
   PubMed Web of Science ®Google Scholar
• Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–873. doi:10.1016/j.jhep.2021.11.030
   PubMed Web of Science ®Google Scholar
• Llovet JM, Villanueva A, Marrero JA, et al. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology. 2021;73(Suppl 1):158–191. doi:10.1002/hep.31327
   PubMed Web of Science ®Google Scholar
• Rimassa L, Personeni N, Czauderna C, Foerster F, Galle P. Systemic treatment of HCC in special populations. J Hepatol. 2021;74(4):931–943. doi:10.1016/j.jhep.2020.11.026
   PubMed Web of Science ®Google Scholar
• Craciun L, de Wind R, Demetter P, et al. Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy. BMC Cancer. 2020;20(1):135. doi:10.1186/s12885-020-6613-1
   PubMed Web of Science ®Google Scholar
• Du SS, Chen GW, Yang P, et al. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation. Int J Radiat Oncol Biol Phys. 2022;112(5):1243–1255. doi:10.1016/j.ijrobp.2021.12.162
   PubMed Web of Science ®Google Scholar
• Sung W, Hong TS, Poznansky MC, Paganetti H, Grassberger C. Mathematical Modeling to Simulate the Effect of Adding Radiation Therapy to Immunotherapy and Application to Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2022;112(4):1055–1062. doi:10.1016/j.ijrobp.2021.11.008
   PubMed Web of Science ®Google Scholar
• Jiang Y, Tu X, Zhang X, et al. Nutrition and metabolism status alteration in advanced hepatocellular carcinoma patients treated with anti-PD-1 immunotherapy. Support Care Cancer. 2020;28(11):5569–5579. doi:10.1007/s00520-020-05478-x
   PubMed Web of Science ®Google Scholar
• Wang D, Hu X, Xiao L, et al. Prognostic Nutritional Index and Systemic Immune-Inflammation Index Predict the Prognosis of Patients with HCC. J Gastrointest Surg. 2021;25(2):421–427. doi:10.1007/s11605-019-04492-7
   PubMed Web of Science ®Google Scholar
• Lim DH, Casadei-Gardini A, Lee MA, et al. Prognostic implication of serum AFP in patients with hepatocellular carcinoma treated with regorafenib. Future Oncol. 2022;18(27):3021–3030. doi:10.2217/fon-2022-0524
   PubMed Web of Science ®Google Scholar
• Galle PR, Foerster F, Kudo M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39(12):2214–2229. doi:10.1111/liv.14223
   PubMed Web of Science ®Google Scholar
• Li X, Xing YF, Lei AH, et al. Neutrophil count is associated with myeloid derived suppressor cell level and presents prognostic value of for hepatocellular carcinoma patients. Oncotarget. 2017;8(15):24380–24388. doi:10.18632/oncotarget.15456
   PubMedGoogle Scholar
• Hong YM, Yoon KT, Hwang TH, Cho M. Pretreatment peripheral neutrophils, lymphocytes and monocytes predict long-term survival in hepatocellular carcinoma. BMC Cancer. 2020;20(1):937. doi:10.1186/s12885-020-07105-8
   PubMed Web of Science ®Google Scholar
• Poto R, Cristinziano L, Modestino L, et al. Neutrophil Extracellular Traps, Angiogenesis and Cancer. Biomedicines. 2022;10(2). doi:10.3390/biomedicines10020431
   PubMed Web of Science ®Google Scholar
• Bihari C, Rastogi A, Shasthry SM, et al. Platelets contribute to growth and metastasis in hepatocellular carcinoma. APMIS. 2016;124(9):776–786. doi:10.1111/apm.12574
   PubMed Web of Science ®Google Scholar
• Pavlovic N, Rani B, Gerwins P, Heindryckx F. Platelets as Key Factors in Hepatocellular Carcinoma. Cancers. 2019;11(7):1022. doi:10.3390/cancers11071022
   PubMed Web of Science ®Google Scholar
• Sung W, Cho B. Modeling of radiation effects to immune system: a review. j Korean Phys Soc. 2022;81(11):1013–1019. doi:10.1007/s40042-022-00574-z
   PubMed Web of Science ®Google Scholar
• Dharmapuri S, Özbek U, Lin JY, et al. Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy. Cancer Med. 2020;9(14):4962–4970. doi:10.1002/cam4.3135
   PubMed Web of Science ®Google Scholar
• Zeng J, Zeng J, Wu Q, et al. Novel inflammation-based prognostic nomograms for individualized prediction in hepatocellular carcinoma after radical resection. Ann Translat Med. 2020;8(17):1061. doi:10.21037/atm-20-1919
   PubMed Web of Science ®Google Scholar
• Pu T, Li ZH, Jiang D, et al. Nomogram based on inflammation-related markers for predicting survival of patients undergoing hepatectomy for hepatocellular carcinoma. World j Clin Cases. 2021;9(36):11193–11207. doi:10.12998/wjcc.v9.i36.11193
   PubMed Web of Science ®Google Scholar